Lyell Immunopharma (LYEL) EBITDA Margin (2020 - 2026)
Lyell Immunopharma (LYEL) posted EBITDA Margin of 2213050.0% for Q1 2026, down 4.03% sequentially from 2127400.0% in Q4 2025, and down 139352143.0% YoY from N/an in Q1 2025.
Lyell Immunopharma (LYEL) EBITDA Margin (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported EBITDA Margin for 7 years, with the latest figure at 2213050.0% in Q1 2026.
- Quarterly EBITDA Margin fell 139352143.0% year-over-year to 2213050.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 826767.74% (down 27208005.0% YoY) and the FY2025 annual result came in at 748344.44%, down 16022149.0% from the prior year.
- EBITDA Margin slipped to 2213050.0% in Q1 2026 per LYEL's latest filing, from 2127400.0% in the prior quarter.
- Over five years, EBITDA Margin peaked at 30.55% in Q4 2022 and troughed at 2214566.67% in Q3 2022.
- A 5-year average of 793232.29% and a median of 396369.23% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2023: EBITDA Margin plunged 221278224 bps in 2022, then surged 197841067 bps in 2023.
- Over 5 years, EBITDA Margin stood at 30.55% in 2022, then plunged by 1498065 bps to 457753.85% in 2023, then sank by 299 bps to 1828609.09% in 2024, then retreated by 16 bps to 2127400.0% in 2025, then fell by 4 bps to 2213050.0% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 2213050.0%, 2127400.0%, and 248353.33% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | -1,183,425.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,183,425.00% |
| Mar 31, 2026 | -2,213,050.00% |
| Dec 31, 2025 | -2,127,400.00% |
| Sep 30, 2025 | -248,353.33% |
| Jun 30, 2025 | -589,250.00% |
| Mar 31, 2025 | -819,528.57% |
| Dec 31, 2024 | -1,828,609.09% |
| Sep 30, 2024 | -148,544.12% |
| Jun 30, 2024 | -396,369.23% |
| Mar 31, 2024 | -1,852,500.00% |
| Dec 31, 2023 | -457,753.85% |
| Sep 30, 2023 | -236,156.00% |
| Jun 30, 2023 | -244,092.59% |
| Mar 31, 2023 | -96,240.00% |
| Dec 31, 2022 | -30.55% |
| Sep 30, 2022 | -2,214,566.67% |
| Jun 30, 2022 | -104.25% |
| Mar 31, 2022 | -12,400.72% |
| Dec 31, 2021 | -1,684.55% |
| Sep 30, 2021 | -1,784.43% |